ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2008
The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 65 citations in OpenAlex.
- Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.Molecular psychiatry · 2026Article
- Evaluation of dECM hydrogel-NAP on 3D organotypic human corneal epithelium in diabetic keratopathy model.Scientific reports · 2026Article
- Regulation of UV-B-Induced Inflammatory Mediators by Activity-Dependent Neuroprotective Protein (ADNP)-Derived Peptide (NAP) in Corneal Epithelium.International journal of molecular sciences · 2023Article
- Activity-Dependent Neuroprotective Protein (ADNP): An Overview of Its Role in the Eye.International journal of molecular sciences · 2022Review
- High-Mobility Group Box 1 Inhibitor BoxA Alleviates Neuroinflammation-Induced Retinal Ganglion Cell Damage in Traumatic Optic Neuropathy.International journal of molecular sciences · 2022Article
- Activity-Dependent Neuroprotective Protein (ADNP)-Derived Peptide (NAP) Counteracts UV-B Radiation-Induced ROS Formation in Corneal Epithelium.Antioxidants (Basel, Switzerland) · 2022Article
- The Protective Effects of Endogenous PACAP in Oxygen-Induced Retinopathy.Journal of molecular neuroscience : MN · 2021Article
- Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy.Pharmaceutics · 2021Review
- PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.Journal of molecular neuroscience : MN · 2021Review
- Age-Related Alterations of Proteins in Albino Wistar Rat Retina.Cells, tissues, organs · 2021Article
- Inherited Eye Diseases with Retinal Manifestations through the Eyes of Homeobox Genes.International journal of molecular sciences · 2020Review
- Topical Brimonidine or Intravitreal BDNF, CNTF, or bFGF Protect Cones Against Phototoxicity.Translational vision science & technology · 2019Article
- Neuroprotective Peptides in Retinal Disease.Journal of clinical medicine · 2019Review
- Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease.Journal of food and drug analysis · 2019Article
- Article
- Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats.Journal of molecular neuroscience : MN · 2017Article
- Shared and Differential Retinal Responses against Optic Nerve Injury and Ocular Hypertension.Frontiers in neuroscience · 2017Review
- Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.Journal of molecular neuroscience : MN · 2016Review
- NAP reduces murine microvascular endothelial cells proliferation induced by hyperglycemia.Journal of molecular neuroscience : MN · 2014Article
- Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death.Journal of molecular neuroscience : MN · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations. We already discovered that NAP increases the survival of retinal ganglion cells (RGC) in vitro, and supports neurite outgrowth in retinal explants at femtomolar concentrations. The aim of this study was to investigate the effects of NAP on RGC survival after transient retinal ischemia and optic nerve crush.
methodsRGC of male Wistar rats were labelled retrogradely with 6 l FluoroGold injected stereotactically into both superior colliculi. Seven days later, retinal ischemia was induced by elevating the intraocular pressure to 120 mm Hg for 60 minutes or by crushing one optic nerve for 10 s after a partial orbitotomy. NAP was either injected intraperitoneally in the concentration of 100 microg/kg [corrected] 1 day before, directly after, and on the first and the second days after damage, or intravitreally (0.05 or 0.5 microg/eye) [corrected] directly after the optic nerve crush. Controls received the same concentrations of a control peptide. Densities of surviving RGC and activated microglial cells (AMC) were quantified in a masked fashion 10 days after damage by counting FluoroGold-labelled cells.
resultsAfter retinal ischemia, intraperitoneal injections of NAP increased the number of surviving RGC by 40% (p < 0.005) compared to the control group. After optic nerve crush, NAP raised the number of surviving RGC by 31% (p = 0.07) when injected intraperitoneally and by 54% (p < 0.05) when administered intravitreally.
conclusionsNAP acts neuroprotectively in vivo after retinal ischemia and optic nerve crush, and may have potential in treating optic nerve diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.